Present and Future Therapy of Cryptococcus Infections
AbstractCryptococcal infections burden the immunocompromised population with unacceptably high morbidity and mortality. This population includes HIV-infected individuals and those undergoing organ transplants, as well as seemingly immunocompetent patients (non-HIV, non-transplant). These groups are difficult to manage with the current therapeutic options and strategies, particularly in resource-limited settings. New trials aimed at providing the best treatment strategies for resource-limited countries that will reduce costs and adverse reactions have focused on decreasing the length of therapy and using more readily accessible antifungal agents such as fluconazole. Furthermore, the emergence of antifungal resistance poses another challenge for successful treatment and may require the development of new agents for improved management. This review will discuss the principles of management, current and future antifungal agents, as well as emerging techniques and future directions of care for this deadly infection. View Full-Text
Share & Cite This Article
Mourad, A.; Perfect, J.R. Present and Future Therapy of Cryptococcus Infections. J. Fungi 2018, 4, 79.
Mourad A, Perfect JR. Present and Future Therapy of Cryptococcus Infections. Journal of Fungi. 2018; 4(3):79.Chicago/Turabian Style
Mourad, Ahmad; Perfect, John R. 2018. "Present and Future Therapy of Cryptococcus Infections." J. Fungi 4, no. 3: 79.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.